Quest PharmaTech deal with OncoCare includes 45% equity stake

29 November 2018

Canada’s Quest PharmaTech (TSX-V: QPT) has entered into a license agreement with US company OncoCare Therapeutics, to develop and commercialize the company's Targeted Cancer Therapy Technology in the USA.

Quest's Targeted Cancer Therapy Technology includes two potential treatments: AR 9.6, an antibody licensed from the University of Nebraska Medical Center that binds to and blocks oncogenic activities of MUC16; and ACP-2127 which targets CDK/mTOR receptors. Both candidates are being developed for the treatment of pancreatic cancer, one of the deadliest diseases with, currently, no significant long-term treatment options.

In return for granting the license rights to the US, Quest will receive a 45% ownership interest in OncoCare Therapeutics, whose management includes Dr Michael (Tony) Hollingsworth and Dr Prakash Radhakrishnan, original inventors of the AR 9.6 technology, and Craig Tuttle, chief executive, an executive with over 20 years' experience in the biotech industry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK